tbuckley/cabot-search huggingface dataset:
Non-Hematopoietic Lymphoid Stromal Cells Prime Alloreactive CD4+ T Cells in Acute Graft-Versus-Host Disease
Authors: Muhammad Shaikh, Maria Ulbrich, Juan Gamboa Vargas, Katja J Ottmüller, Duc Dung Le, Zeinab Mokthari, Joern Pezoldt, Hermann Einsele, Burkhard Ludewig, Jochen Huehn, Andreas Beilhack
Journal: Blood (2019)
PDTM-16. PEDIATRIC HIGH GRADE GLIOMA RESOURCES FROM THE CHILDREN’S BRAIN TUMOR TISSUE CONSORTIUM (CBTTC) AND PEDIATRIC BRAIN TUMOR ATLAS (PBTA)
Authors: Heba Ijaz, Mateusz Koptyra, Krutika Gaonkar, Jo Lynne Rokita, Valerie Baubet, Lamiya Tauhid, Yuankun Zhu, Miguel Brown, Gonzalo Lopez, Bo Zhang, Sharon Diskin, Zalman Vaksman, Jennifer Mason, Elizabeth Appert, Jena Lilly, Rishi Lulla, Thomas De Raedt, Allison Heath, Alex Felmeister, Pichai Raman, Javad Nazarian, Mariarita Santi, Phillip Storm, Adam Resnick, Angela Waanders, Kristina Cole
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Pediatric high grade glioma (pHGG) remains a fatal disease. Access to richly annotated biospecimens and patient derived tumor models will accelerate pHGG research and support translation of research discoveries. This work describes the pediatric high grade glioma set of the Children’s Brain Tumor Tissue Consortium (CBTTC) from the first release of the Pediatric Brain Tumor Atlas (PBTA). METHODS pHGG tumors with associated clinical data and imaging were prospectively collected through the CBTTC and analyzed as the Pediatric Brain Tumor Atlas (PBTA) with processed genomic data deposited into PedcBioPortal for broad access and visualization. Matched tumor was cultured to create high grade glioma cell lines analyzed by targeted and WGS and RNA-seq. A tissue microarray (TMA) of primary pHGG tumors was also created. RESULTS The pHGG set includes 87 collection events (73 patients, 60% at diagnosis, median age of 9 yrs, 55% female, 46% hemispheric). Operative reports, pathology reports and histology images are available for nearly all cases. Pre- and post-operative MRI images and reports are also available for a subset. Tumor WGS/RNAseq is available for 70 subjects. Analysis of somatic mutations and copy number alterations of known glioma genes were of expected distribution (36% H3.3, 47% TP53, 24% ATRX and 7% BRAFV600E variants). In our panel of pHGG, six patients (8 tumors) harbored germline mismatch repair mutations with tumor hyper-mutation. A pHGG TMA (n=77), includes 36 patient tumors with matched sequencing. At least one established glioma cell line was generated from 23 patients (32%). Unique reagents include those derived from a H3.3 G34R glioma and from tumors with mismatch repair deficiency. CONCLUSION The CBTTC and PBTA have created an openly available integrated resource of over 2,000 tumors, including a rich set of pHGG primary tumors, corresponding cell lines and archival fixed tissue to advance translational research for pHGG.
Infusion of Mesenchymal Stem Cells Combined with Epithelial Progenitor Cells Promotes Injured Intestinal Repairing after Hematopoietic Cell Transplantation
Authors: Shengyun Zhu, Huiqi Li, Chaoran Lyu, Jing Liang, Lingyu Zeng, Kailin Xu
Journal: Blood (2019)
A Personalized Prediction Model to Risk Stratify Patients with Acute Myeloid Leukemia (AML) Using Artificial Intelligence
Authors: Jacob Shreve, Manja Meggendorfer, Hassan Awada, Sudipto Mukherjee, Wencke Walter, Stephan Hutter, Ahed Makhoul, Cameron Beau Hilton, Nathan Radakovich, Yasunobu Nagata, Yazan Rouphail, Vera Adema, Cassandra M Kerr, Bhumika J. Patel, Teodora Kuzmanovic, Jaroslaw P. Maciejewski, Claudia Haferlach, Mikkael A. Sekeres, Torsten Haferlach, Aziz Nazha
Journal: Blood (2019)
Combined Infusion of Anti-CD19 and Anti-Bcma CART Cells after Early or Later Transplantation in the Front Line Was Superior to Salvage Therapy for High Risk MM
Authors: Xiaolan Shi, Lingzhi Yan, Jingjing Shang, Liqing Kang, Song Jin, Huizhu Kang, Ruju Wang, Zhu Mingqing, Jiazi Zhou, Feiran Gong, Guanghua Chen, Jin Zhou, Huirong Chang, Weiqin Yao, Ying Yao, Yong Liu, Zhi Yan, Juanjuan Su, Depei Wu, Lei Yu, Fu Cheng Cheng
Journal: Blood (2019)
CEBPα Mutations in Childhood Acute Myeloid Leukemia.
Authors: Der-Cherng Liang, Lee-Yung Shih, Chein-Fuang Huang, Iou-Jih Hung, Chao-Ping Yang, Hsi-Che Liu, Tang-Her Jaing, Lin-Yen Wang, Wan-Hui Chang
Journal: Blood (2004)
Guselkumab is superior to fumaric acid esters in patients with moderate‐to‐severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active‐comparator‐controlled phase IIIb trial (POLARIS)
Authors: D. Thaçi, A. Pinter, M. Sebastian, C. Termeer, M. Sticherling, S. Gerdes, S. Wegner, S. Krampe, H. Bartz, C. Rausch, A. Mensch, K. Eyerich
Journal: British Journal of Dermatology (2019)

Guselkumab, a fully human interleukin-23 antibody, is approved for systemic treatment of patients with moderate-to-severe plaque psoriasis.To compare the efficacy and safety of guselkumab with those of fumaric acid esters (FAE) in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment.Eligible patients were randomized to this multicentre, randomized, open-label, assessor-blinded, active-comparator-controlled phase IIIb study to receive guselkumab 100 mg by subcutaneous injection or oral FAE according to local label guidelines.Through week 24, 56 of 60 patients completed guselkumab treatment and 36 of 59 completed FAE treatment. The primary endpoint (proportion of patients with ≥ 90% improvement from their baseline Psoriasis Area and Severity Index; PASI 90 response) was achieved by significantly more patients receiving guselkumab than FAE at week 24 (82% vs. 14%, P < 0·001). Analysis of the major secondary endpoints confirmed a statistically significant difference between the treatments with regards to PASI 75 response (90% vs. 27%, P < 0·001) and Dermatology Life Quality Index score of 0 or 1 (no effect at all on the patient's quality of life; 62% vs. 17%, P < 0·001). More patients in the guselkumab group achieved completely clear skin (PASI 100 response) than in the FAE group (32% vs. 3%, P < 0·001). The incidence of adverse events was lower with guselkumab than with FAE (73% vs. 98%). Overall, 28% of patients on FAE discontinued due to an adverse event, compared with none receiving guselkumab. No new safety findings were observed for guselkumab.Guselkumab demonstrated superiority over FAE in systemic-treatment-naive patients with moderate-to-severe plaque psoriasis through 24 weeks.
Head-to-Head Comparison of Haploidentical HSCT Strategies for Hematologic Malignancies: Phase III Hatcy Study of T-Cell-Depleted HSCT with Adjunctive ATIR101 Versus T-Cell-Replete HSCT with Post‐Transplant Cyclophosphamide
Authors: Denis Claude Roy, Bernd-Jan Sanson, Jonas Hylton, Andrew Sandler, Stephan Mielke
Journal: Blood (2019)
Why Are Some Driver Mutations Rare?
Authors: Ruth Nussinov, Chung-Jung Tsai, Hyunbum Jang
Journal: Trends in Pharmacological Sciences (2019)

Understanding why driver mutations that promote cancer are sometimes rare is important for precision medicine since it would help in their identification. Driver mutations are largely discovered through their frequencies. Thus, rare mutations often escape detection. Unlike high-frequency drivers, low-frequency drivers can be tissue specific; rare drivers have extremely low frequencies. Here, we discuss rare drivers and strategies to discover them. We suggest that allosteric driver mutations shift the protein ensemble from the inactive to the active state. Rare allosteric drivers are statistically rare since, to switch the protein functional state, they cooperate with additional mutations, and these are not considered in the patient cancer-specific protein sequence analysis. A complete landscape of mutations that drive cancer will reveal tumor-specific therapeutic vulnerabilities.
Pre-Engraftment Immune Reactions Has Unique Graft-Versus-Leukemia Effects after Single Cord Blood Transplantation
Authors: Yamamoto Hisashi, Naoyuki Uchida, Mitsuhiro Yuasa, Kosei Kageyama, Daisuke Kaji, Takashi Mitsuki, Yuki Taya, Aya Nishida, Kazuya Ishiwata, Shinsuke Takagi, Yuki Asano-Mori, Go Yamamoto, Atsushi Wake, Shuichi Taniguchi
Journal: Blood (2019)
Cross Talk between the Immune Compartment and the Tumor Cells in Myelodysplastic Syndromes (MDS)
Authors: Camille Bigenwald, Amir Horowitz, Shyamala C. Navada, Rosalie Odchimar-Reissig, Richa Rai, Stella Melana, Erin P. Demakos, Miriam Merad, Lewis R. Silverman
Journal: Blood (2019)
CSIG-15. INHIBITION OF THE bHLH TRANSCRIPTIONAL NETWORKS BY A MUTATED E47 PROTEIN LEADS TO A STRONG ANTI-GLIOMA ACTIVITY IN VITRO AND IN VIVO
Authors: Marilin Koch, Stefan Czemmel, Felix Lennartz, Sarah Beyeler, Justyna Przystal, Parameswari Govindarajan, Denis Canjuga, Manfred Neumann, Patrizia Rizzu, Marcos Tatagiba, Sven Nahnsen, Peter Heutink, Olivier Raineteau, Ghazaleh Tabatabai
Journal: Neuro-Oncology (2019)

Abstract OBJECTIVE The transcription factor E47 heterodimerizes with helix-loop-helix (HLH) and basic helix-loop-helix transcription (bHLH) factors like ID-1 and Olig2 that are overexpressed in glioblastoma. A dominant-negative variant of the E47 (dnE47) lacking the nuclear translocation signal, leads to cytoplasmatic sequestration of HLH and bHLH transcription factors. Here, we investigated combinations of dnE47-mediated inhibition of the bHLH transcriptional network with temozolomide and irradiation and explored the underlying molecular mechanisms. METHODS Long-term and stem cell glioma lines were transduced with a Doxycycline-inducible dnE47 lentivirus. Functional characterizations included immunocytochemistry, immunoblots, cytotoxicity and clonogenicity assays in vitro and latency until the onset of symptoms in vivo. CAGE and RNASeq were conducted for analyzing the dnE47-induced molecular profile. RESULTS The induction of dnE47 led to cytoplasmatic sequestration of HLH/bHLH transcription, reduced proliferation, increased cytotoxicity and reduced clonogenic survival in vitro and a prolonged latency until the onset of neurological symptoms in vivo. CAGE and RNASeq data revealed alterations in several cancer-relevant pathways. CONCLUSIONS A dnE47-mediated inhibition of the bHLH transcription network induced actionable molecular alterations in glioma cells that could be exploited for the design of novel therapies.
Exercise training in COPD with exercise-induced desaturation does improve exercise capacity, irrespective of whether supplemental oxygen or air is provided during training
Authors: Jennifer A. Alison, Zoe J. McKeough, Regina W.M. Leung, Anne E. Holland, Kylie Hill, Norman R. Morris, Sue Jenkins, Lissa M. Spencer, Catherine J. Hill, Annemarie L. Lee, Helen Seale, Nola Cecins, Christine F. McDonald
Journal: European Respiratory Journal (2019)

<b>In people with COPD who desaturate during exercise, similar improvements in exercise capacity and health-related quality of life can be achieved with exercise training, irrespective of whether supplemental oxygen or air is provided during training</b>http://bit.ly/2kKGGvi
Autoimmunity in Iron-deficiency Anaemia
Authors: B. Moulton
Journal: BMJ (1964)

One vaginal examination at six weeks should be quite sufficient in the majority of cases.Where symptoms or signs suggest erosion, infection, or sub-involution, then by all means modify this, but I cannot accept that it must always be done routinely, and particularly so on the-tenth day.Likewise, if one has followed the haemoglobin ante- natally and it has been satisfactory prior to delivery; and one has been present at delivery and estimated the total loss to be minimal, why repeat it ?Isn't this meddlesome midwifery-or is it just that I am " not with it " ?-I am, etc., West Malling, Kent.J. STUART BROWN.SIR,-Dr.John Gibbens (11 July, p. 125) may be right in contesting a statement that puerperal mastitis will respond to benzylpenicillin, since staphylococci are now so often resistant.But he himself has fallen into error in suggesting ampicillin instead.Methicillin, yes, or cloxacillin, but ampicillin is just as easily destroyed as benzylpenicfllin by staphylococcal penicillinase.-Iam, etc.,
A Role for TNF-α in Chronic Lymphocytic Leukemia Bone Marrow Hematopoietic Dysfunction
Authors: Bryce A Manso, Jordan Krull, Kimberly Gwin, Petra Lothert, Charla R Secreto, Wei Ding, Sameer A. Parikh, Anne J Novak, Neil E. Kay, Kay L. Medina
Journal: Blood (2019)
CD155-Tigit Pathway Modulation in Dendritic Cell/Acute Myeloid Leukemia Fusion Vaccine Model
Authors: Myrna Nahas, Dina Stroopinsky, Marzia Capelletti, Jacalyn Rosenblatt, Shira Orr, Haider Ghiasuddin, Adam Morin, Jessica Liegel, Donald Kufe, David E. Avigan
Journal: Blood (2019)
PATH-61. IMMUNOHISTOCHEMICAL PHENOTYPING AND SURVIVAL ANALYSIS OF WHO GRADE II-IV GLIOMAS
Authors: Nora Poulos, Srikar Sattiraju, Charles Opalak, Mikhail Dozmorov, Jason Harrison, Hope Richard, William Broaddus
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Specific genetic mutations are linked to clinical prognosis in gliomas. There has been increasing demand to understand the association between tissue biomarker expression and survival. Using patient-derived samples, WHO grade II-IV gliomas were evaluated by the protein-staining pattern of molecular markers of interest across tumor grade, and the association between their expression and survival was investigated. METHODS Tissue microarrays (TMA) containing duplicate 1 mm cores were generated from 78 gliomas (WHO grade II-IV) using an automated TMA system. Immunohistochemistry was performed per the manufactures recommendation to evaluate expression of: Wilms tumor 1 (WT1), platelet endothelial cell adhesion molecule (CD31), adhesion G protein-coupled receptor E5 (CD97), complement decay-accelerating factor (CD55), hypoxia inducible factor 1 subunit alpha (HIF1α), EGF-like module-containing mucin-like hormone receptor-like 3 (EMR3), integrin, and isocitrate dehydrogenase 1 (IDH1). Samples with moderate (+1) or intense (+2) staining to WT1, CD31, CD97, CD55, or HIF1α, or any staining to EMR3 or IDH1 mutation, were considered positive. RESULTS Of the 78 tumor samples, there were 11 (14%) WHO grade II, 22 (28%) grade III, and 45 (59%) grade IV gliomas. Across grade III gliomas, anaplastic astrocytomas had significantly higher positive WT1 (p=0.04), CD31 (p=0.002) and IDH1 wild-type (p&lt; 0.0001) staining. High-grade (III &amp; IV) gliomas had significantly higher positive staining for WT1 (p=0.013), CD31 (0.024), integrin (p=0.021), and IDH1 wild type (p=0.044). In all gliomas, positive staining for WT1 (p&lt; 0.0001), CD31 (p=0.009), CD97 (p=0.024), EMR3 (p=0.036), and IDH1 wild type (p=0.0006) were associated with worse overall survival. After adjusting for patient age, positive staining for WT1 (p=0.003) was associated with worse overall survival. CONCLUSION Using immunohistochemistry, unique biomarker staining patterns were identified for WHO grade III anaplastic astrocytomas and for high-grade gliomas. Irrespective of grade, staining for WT1, CD97, CD31, EMR3, and IDH1 wild-type were associated with worse overall survival.
Abortion and the Psychiatrist
Authors: J. Hoenig
Journal: BMJ (1963)

If a uniformly high standard of ante- natal care is to be guaranteed throughout the U.K. I see no alternative but to provide it at existing hospital antenatal clinics.The increased attendances resulting from such a centralization could be accommodated by recruiting well- qualified G.P.-obstetricians as clinical assistants, who would surely welcome the facilities and staff which at present are -denied them.Even health centres, where they exist, do not provide the continuous postgraduate training of a hospital environment.-I am, etc.,
Host Immune Status Determines the Effects of Therapeutic Interleukin-2 Administration: Enhancement of GVL or Induction of Tolerance?
Authors: Yusuke Meguri, Takeru Asano, Takanori Yoshioka, Haruka Izumi, Yuriko Kishi, Yoshinobu Maeda, Mitsune Tanimoto, Ken-ichi Matsuoka
Journal: Blood (2014)
Hyper-Sialylated IgG M254, an Innovative Therapeutic Candidate, Evaluated in Healthy Volunteers and in Patients with Immune Thrombocytopenia Purpura: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics
Authors: Santiago Arroyo, Renger G Tiessen, William S Denney, Jim Jin, Mattheus Paulus (Thijs) van Iersel, Heidi Zeitz, Anthony M Manning, Martin R. Schipperus, James B. Bussel
Journal: Blood (2019)
GENE-12. ANALYSIS OF FAILURE PATTERNS IN MALIGNANT GLIOMA: EXPLORING THE GENETIC LANDSCAPE OF PATTERN OF FAILURE
Authors: Seung Won Choi, Do-Hyun Nam, Jason Sa, Harim Koo
Journal: Neuro-Oncology (2019)

Abstract Failure patterns in malignant gliomas have been described in previous literatures, however, studies were limited to analyze clinical features to account for predisposition to distinct failure patterns. Present study aimed to describe the landscape of failure patterns in malignant glioma from large cohort by integrating multi-omics data and investigate the genetic backgrounds of distinct failure patterns. A total of 423 cases from 325 patients who enrolled at the registry of IRCR at SMC were reviewed for their pattern of failure. Failure patterns were categorized into local, distant recurrence and leptomeningeal seeding regarding recurrent tumors’ spatial relation to primary location. Genomic data was available for 327 (DNAseq) and 259 samples (RNAseq), respectively. Glioblastoma was the most prevalent histologic type in study cohort (81.2%)) and majority of cases experienced the recurrence (79.0%). None of clinical parameters (e.g. age, sex, extent of operation and history of prior therapy) failed to show any significant association with failure patterns. Although local recurrence was most prevalent (63.8%) among failure patterns in malignant gliomas, considerable portion of patients (37.8%) demonstrated other types of failure patterns even in their initial relapse. Multivariate analysis demonstrated that failure pattern was significant prognostic factor to overall survival (remote recurrence, HR=1.59, p-value=0.009; leptomeningeal seeding, HR=2.17, p-value&lt; 0.001). Genomic analysis including mutational profile revealed distinct molecular landscape of malignant gliomas according to failure patterns, which suggested that innate biologic characteristics of tumors might contribute to develop distinct failure patterns upon recurrence. PTEN mutation was significantly enriched in tumors of distant recurrence (p-value=0.026). We described the landscape of failure patterns in malignant gliomas by integrating clinical and genomic data. Considerable amount of malignant glioma patients experienced distinct failure patterns other than local recurrence and their clinical outcome as well as genetic background demonstrated invasive characteristic of these tumors.
Rapid Dose Escalation of Venetoclax in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Previously Treated with B-Cell Receptor Inhibitor Therapy
Authors: Kristin Koenig, Emily Dotson, Shane Sheredy, Seema A. Bhat, John C. Byrd, Tracy Wiczer, Jennifer Woyach, Farrukh T. Awan, Kerry A. Rogers
Journal: Blood (2019)
First Results of the Interdisciplinary Comprehensive Cancer Center Freiburg (CCCF) Tumor Board (TB) Multiple Myeloma (MM) Assessing TB-Questions, TB-Advice Adherence, TB-Satisfaction of Patients, Participants and Referring Physicians, Inclusion of Difficult-to-Treat-MM Pts in Clinical Trials (CT) and Patient Outcome
Authors: Ricarda Selder, Masa Pandurevic, Mandy-Deborah Möller, Johannes Waldschmidt, Milena Pantic, Georg W. Herget, Karl Henne, Annette May, Martina Kleber, Josefina Udi, Gabriele Ihorst, Rainer Bredenkamp, Werner Vach, Justus Duyster, Ralph Wäsch, Monika Engelhardt
Journal: Blood (2014)
Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients
Authors: Josep-Maria Ribera, Olga García, Marta Cervera, Carlos Rguez, Maialen Sirvent, Ferran Vall-Llovera, Pau Abrisqueta, Josefina Serrano, Buenaventura Buendía, Pau Montesinos Fernandez, Susana Vives, Juan Miguel Bergua Burgues, Mariana Beatriz Bastos-Oreiro, Evelyn Acuña, María José Moreno, Irene García-Cadenas, Maria Jose Terol, Jesús María Hernández-Rivas, Antonio Garcia-Guiñon, Pilar Herrera Puente, Santiago Mercadal, Iulia Ivan, Antonia Cladera, Eva Gimeno Vázquez, Anna Torrent, Alfons Serrano-Maestro, Cristina Barrenetxea, Daniel García, Reyes Arranz, Ana Sebrango, Natalia Alonso, Daniel Martínez-Carballeira, Juan-Manuel Sancho
Journal: Blood (2019)
QOLP-27. CLINICAL FACTORS AND MOLECULAR MARKERS ASSOCIATED WITH POSTOPERATIVE SEIZURES IN GLIOBLASTOMA
Authors: Ankush Chandra, Ishan Kanungo, Jonathan Rick, John Yue, Fara Dayani, Alan Nguyen, Patrick Flanigan, Edward Chang, Mike McDermott, Mitchel Berger, Manish Aghi
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Glioblastoma has a poor prognosis, further complicated by postoperative seizures. We analyzed various factors associated with postoperative seizures in glioblastoma. METHODS Retrospective chart review of 932 patients who underwent craniotomy for glioblastoma (777=83.4% newly diagnosed; 155=16.6% recurrent) at our institution (2002–2014). Postoperative seizures were defined as those occurring within 14 days of surgery. RESULTS Our cohort consisted of 49.9% (n=465) males with mean age of 55.8 (range 9–91) years. In total, 69 (7.4%) had postoperative seizures with mean time from surgery to seizure of 3.1 days (IQR=1–4). Of 536 patients (57.5%) receiving seizure prophylaxis, those treated with Keppra were more likely to have postoperative seizures compared to those on Dilantin (10.9% vs 5.0%; p=0.022). Primary tumor patients were less likely to seize postoperatively compared to recurrent tumor patients (9.7% vs 19%; p=0.016). Patients presenting with seizure as chief complaint (12.1% vs 5.1%; p=0.025) and those with &gt;20% of Chromosome 10 deletion were more likely to have seizures postoperatively (12.4% vs 6.1%; p=0.0029). Risk factors for postop seizures for newly-diagnosed patients included subtotal resection versus gross total resection (28.0% vs 7.1%; p=0.022). Risk factors for postop seizures for recurrent patients were &gt;5% EGFR amplification (23.5% vs 5.8%; p=0.0021) and hyponatremia within mean 2.5 days (IQR 0–1) after surgery (20.8% vs 7.1%; p=0.035). CONCLUSION We identified several risk factors for postoperative seizures in glioblastoma patients, most of which were clinical (seizure as chief complaint, the antiepileptic chosen for prophylaxis, and extent of resection), while some were molecular and linked to genes whose products have demonstrated links to epileptogeneicity (Chromosome 10, EGFR). These findings may assist physicians in detecting glioblastoma patients that are at higher risk for postoperative seizures and in providing prophylaxis to reduce morbidity.
Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110β/δ Inhibitor in Patients with Relapsed/Refractory (R/R) B-Cell Lymphoma
Authors: Loretta J. Nastoupil, Sattva S Neelapu, Eric Davis, Felipe Samaniego, Nathan H Fowler, Jason R. Westin, Hun Ju Lee, Michael Wang, Fredrick B. Hagemeister, Philip Beer, Alexander R. L. Cecil, James Dow, Duncan McHale, Franck Silva, Penny Ward, Arash Yavari, Stephen Joseph Shuttleworth
Journal: Blood (2019)
Flavors of e-Cigarettes Used by Youths in the United States
Authors: Adam M. Leventhal, Richard Miech, Jessica Barrington-Trimis, Lloyd D. Johnston, Patrick M. O’Malley, Megan E. Patrick
Journal: JAMA (2019)

Karen A. Cullen, PhD; Andrea S. Gentzke, PhD; Michael D. Sawdey, PhD; Joanne T. Chang, PhD; Gabriella M. Anic, PhD; Teresa W. Wang, PhD; MeLisa R. Creamer, PhD; Ahmed Jamal, MBBS; Bridget K. Ambrose, PhD; Brian A. King, PhD